News

Under the terms of agreement, Grifols takes a further step towards the consolidation of its diagnostic division, expanding its range of products with the immunohematology technology. Progenika and

In Cell Art’s ICAntibodies is an integrated process for antigen design, nanocarriers/DNA formulation and genetic immunisation in mice, rats and rabbits. In the absence of recombinant protein, In

Amylin and Lilly have presented the findings of the trial at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla. The retrospective study

Codexis has commercialised its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. Codexis said

The Phase 3 clinical trial is designed as a multi-center, randomised, crossover, outpatient study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of every 12-hour DR Cysteamine

XmAb5574, which will be renamed MOR208, is a humanised anti-CD19 monoclonal antibody for the treatment of B-cell malignancies. The contract provides MorphoSys with an exclusive worldwide license to

According to the study the addition of Dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated

According to OraSure Technologies, OraQuick is a test strip and does not require an instrument for diagnosis. It takes about 20 minutes to obtain results from the test

NCX 434 is a nitric oxide (NO)-donating new molecular entity (NME) and a potential preclinical candidate in diabetic macular edema (DME). NicOx’s new preclinical study demonstrated that NCX